Rapid hematopoietic recovery after multicycle high-dose chemotherapy: Enhancement of filgrastim-induced progenitor-cell mobilization by recombinant human stem-cell factor

被引:27
作者
Basser, RL [1 ]
To, LB
Begley, CG
Maher, D
Juttner, C
Cebon, J
Mansfield, R
Olver, I
Duggan, G
Szer, J
Collins, J
Schwartz, B
Marty, J
Menchaca, D
Sheridan, WP
Fox, RM
Green, MD
机构
[1] Royal Melbourne Hosp, Ctr Dev Canc Therapeut, Parkville, Vic 3050, Australia
[2] Ludwig Inst Canc Res, Melbourne Tumour Biol Branch, Epalinges, Switzerland
[3] Royal Melbourne Hosp, Rotary Bone Marrow Res Labs, Dept Surg, Dept Hematol & Med Oncol, Melbourne, Vic, Australia
[4] Walter & Eliza Hall Inst Med Res, Parkville, Vic, Australia
[5] Hanson Ctr Canc Res, Adelaide, SA, Australia
[6] Amgen Australia, Kew, Vic, Australia
[7] Amgen, Thousand Oaks, CA USA
关键词
D O I
10.1200/JCO.1998.16.5.1899
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To assess the mobilization potential and safety of recombinant human stem-cell factor (SCF) when coadministered with filgrastim to untreated women with poor-prognosis breast cancer Patients and Methods: Eligible women had breast cancer with 10 or more positive axillary nodes, or estrogen receptor-negative tumor with 4 positive nodes, or stage III disease. Patients were randomized to receive SCF plus filgrastim or filgrastim alone. Filgrastim 12 mu g/kg daily was administered for 6 days by continuous subcutaneous infusion. SCF was administered by dairy subcutaneous injection at 5, 10, or 15 mu g/kg concurrent with filgrastim for 7 days, or 10 mu g/kg daily starting 3 days before filgrastim for a total of 10 days (SCF pretreatment). Apheresis was performed on days 5, 6, and 7 of filgrastim administration. Patients then had three cycles of epirubicin 200 mg/m(2) and cyclophosphamide 4 g/m(2) every 28 days, each supported by one third of the apheresis product. Results: Sixty-two women were treated. Greater yields occurred in patients who received SCF 10 mu g/kg daily plus filgastim than those who received filgrastim alone (P =.013 for CD34(+) cells; P =.07 far granulocyte-macrophage colony-forming cells [GM-CFCs]). The difference was more marked with SCF-pretreatment than concurrent SCF. Fewer aphereses were required to reach the predetermined target of peripheral-blood progenitor/stem cells (PBPCs) in women who received SCF. SCF was generally well tolerated. Hematologic recovery was rapid after each of the three cycles of chemotherapy. There was no difference in recovery between the different treatment groups. Conclusion: Mobilization of PBPCs by filgrastim is significantly enhanced by coadministration of SCF, and commencing SCF before filgrastim can optimize this effect. SCF has the potential to reduce the number of aphereses required to collect a target number of PBPCs.
引用
收藏
页码:1899 / 1908
页数:10
相关论文
共 55 条
[1]   RAPID ENGRAFTMENT BY PERIPHERAL-BLOOD PROGENITOR CELLS MOBILIZED BY RECOMBINANT HUMAN STEM-CELL FACTOR AND RECOMBINANT HUMAN GRANULOCYTE-COLONY-STIMULATING FACTOR IN NONHUMAN-PRIMATES [J].
ANDREWS, RG ;
BRIDDELL, RA ;
KNITTER, GH ;
ROWLEY, SD ;
APPELBAUM, FR ;
MCNIECE, IK .
BLOOD, 1995, 85 (01) :15-20
[2]  
ANDREWS RG, 1991, BLOOD, V78, P1975
[3]  
ANDREWS RG, 1994, BLOOD, V84, P800
[4]   High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America [J].
Antman, KH ;
Rowlings, PA ;
Vaughan, WP ;
Pelz, CJ ;
Fay, JW ;
Fields, KK ;
Freytes, CO ;
Gale, RP ;
Hillner, BE ;
Holland, HK ;
Kennedy, MJ ;
Klein, JP ;
Lazarus, HM ;
McCarthy, PL ;
Saez, R ;
Spitzer, G ;
Stadtmauer, EA ;
Williams, SF ;
Wolff, S ;
Sobocinski, KA ;
Armitage, JO ;
Horowitz, MM .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (05) :1870-1879
[5]  
BASSER R, 1997, P AN M AM SOC CLIN, V16, pA120
[6]  
Basser RL, 1995, CLIN CANCER RES, V1, P715
[7]   Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer [J].
Basser, RL ;
Rasko, JEJ ;
Clarke, K ;
Cebon, J ;
Green, MD ;
Hussein, S ;
Alt, C ;
Menchaca, D ;
Tomita, D ;
Marty, J ;
Fox, RM ;
Begley, CG .
LANCET, 1996, 348 (9037) :1279-1281
[8]  
Basser RL, 1997, BLOOD, V89, P3118
[9]   Enhanced levels and enhanced clonogenic capacity of blood progenitor cells following administration of stem cell factor plus granulocyte colony-stimulating factor to humans [J].
Begley, CG ;
Basser, R ;
Mansfield, R ;
Thomson, B ;
Parker, WRL ;
Layton, J ;
To, B ;
Cebon, J ;
Sheridan, WP ;
Fox, RM ;
Green, MD .
BLOOD, 1997, 90 (09) :3378-3389
[10]  
Bensinger WI, 1996, BLOOD, V88, P4132